Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014 (2014), Article ID 751859, 13 pages
http://dx.doi.org/10.1155/2014/751859
Review Article

Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes

Endocrinology Department, Jinan Central Hospital Affiliated to Shandong University, No. 105 Jiefang Road, Jinan, Shandong 250013, China

Received 2 January 2014; Accepted 9 April 2014; Published 28 April 2014

Academic Editor: Khalid Hussain

Copyright © 2014 Lin Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. L. J. Everett and M. A. Lazar, “Cell-specific integration of nuclear receptor function at the genome,” Wiley Interdisciplinary Reviews-Systems Biology and Medcine, vol. 5, no. 5, pp. 615–629, 2013. View at Google Scholar
  3. N. Y. Kalaany and D. J. Mangelsdorf, “LXRs and FXR: the Yin and Yang of cholesterol and fat metabolism,” Annual Review of Physiology, vol. 68, no. 1, pp. 159–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Xiao, P. Wang, and K.-C. Chou, “Recent progresses in identifying nuclear receptors and their families,” Current Topics in Medicinal Chemistry, vol. 13, no. 10, pp. 1192–1200, 2013. View at Google Scholar
  5. W. Seol, H.-S. Choi, and D. D. Moore, “Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors,” Molecular Endocrinology, vol. 9, no. 1, pp. 72–85, 1995. View at Google Scholar · View at Scopus
  6. B. M. Forman, E. Goode, J. Chen et al., “Identification of a nuclear receptor that is activated by farnesol metabolites,” Cell, vol. 81, no. 5, pp. 687–693, 1995. View at Google Scholar · View at Scopus
  7. D. J. Parks, S. G. Blanchard, R. K. Bledsoe et al., “Bile acids: natural ligands for an orphan nuclear receptor,” Science, vol. 284, no. 5418, pp. 1365–1368, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Fiorucci, A. Mencarelli, E. Distrutti, G. Palladino, and S. Cipriani, “Targeting farnesoid-X-receptor: from medicinal chemistry to disease treatment,” Current Medicinal Chemistry, vol. 17, no. 2, pp. 139–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Otte, H. Kranz, I. Kober et al., “Identification of farnesoid X receptor β as a novel mammalian nuclear receptor sensing lanosterol,” Molecular and Cellular Biology, vol. 23, no. 3, pp. 864–872, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. P. J. Willy, K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J. Mangelsdorf, “LXR, a nuclear receptor that defines a distinct retinoid response pathway,” Genes and Development, vol. 9, no. 9, pp. 1033–1045, 1995. View at Google Scholar · View at Scopus
  11. C. Song, J. M. Kokontis, R. A. Hiipakka, and S. Liao, “Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 10809–10813, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. B. A. Janowski, P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf, “An oxysterol signalling pathway mediated by the nuclear receptor LXRα,” Nature, vol. 383, no. 6602, pp. 728–731, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Viennois, K. Mouzat, J. Dufour, L. Morel, J.-M. Lobaccaro, and S. Baron, “Selective liver X receptor modulators (SLiMs): what use in human health?” Molecular and Cellular Endocrinology, vol. 351, no. 2, pp. 129–141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Xu, L.-X. Pan, H. Li et al., “Regulation of the farnesoid X receptor (FXR) by bile acid flux in rabbits,” Journal of Biological Chemistry, vol. 277, no. 52, pp. 50491–50496, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. T. T. Lu, M. Makishima, J. J. Repa et al., “Molecular basis for feedback regulation of bile acid synthesis by nuclear receptos,” Molecular Cell, vol. 6, no. 3, pp. 507–515, 2000. View at Google Scholar · View at Scopus
  16. B. Goodwin, S. A. Jones, R. R. Price et al., “A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis,” Molecular Cell, vol. 6, no. 3, pp. 517–526, 2000. View at Google Scholar · View at Scopus
  17. B. Kong, L. Wang, J. Y. L. Chiang, Y. Zhang, C. D. Klaassen, and G. L. Guo, “Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice,” Hepatology, vol. 56, no. 3, pp. 1034–1043, 2012. View at Google Scholar
  18. Y.-K. Lee, D. R. Schmidt, C. L. Cummins et al., “Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis,” Molecular Endocrinology, vol. 22, no. 6, pp. 1345–1356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Inagaki, M. Choi, A. Moschetta et al., “Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis,” Cell Metabolism, vol. 2, no. 4, pp. 217–225, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Gupta, R. T. Stravitz, P. Dent, and P. B. Hylemon, “Down-regulation of cholesterol 7alpha -hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 15816–15822, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Zhang, “Transcriptional regulation of the human sterol 12alpha -hydroxylase gene (CYP8B1),” Journal of Biological Chemistry, vol. 276, no. 45, pp. 41690–41699, 2001. View at Google Scholar · View at Scopus
  22. I. Kim, S.-H. Ahn, T. Inagaki et al., “Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine,” Journal of Lipid Research, vol. 48, no. 12, pp. 2664–2672, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Wang, Y.-K. Lee, D. Bundman et al., “Redundant pathways for negative feedback regulation of bile acid production,” Developmental Cell, vol. 2, no. 6, pp. 721–731, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Zollner and M. Trauner, “Nuclear receptors as therapeutic targets in cholestatic liver diseases,” British Journal of Pharmacology, vol. 156, no. 1, pp. 7–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. E. De Fabiani, N. Mitro, F. Gilardi, D. Caruso, G. Galli, and M. Crestani, “Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle,” Journal of Biological Chemistry, vol. 278, no. 40, pp. 39124–39132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. C. J. Sinal, M. Tohkin, M. Miyata, J. M. Ward, G. Lambert, and F. J. Gonzalez, “Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis,” Cell, vol. 102, no. 6, pp. 731–744, 2000. View at Google Scholar · View at Scopus
  27. G. L. Guo, G. Lambert, M. Negishi et al., “Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity,” Journal of Biological Chemistry, vol. 278, no. 46, pp. 45062–45071, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. P. C. Pircher, J. L. Kitto, M. L. Petrowski et al., “Farnesoid X receptor regulates bile acid-amino acid conjugation,” Journal of Biological Chemistry, vol. 278, no. 30, pp. 27703–27711, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Gnerre, S. Blättler, M. R. Kaufmann, R. Looser, and U. A. Meyer, “Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene,” Pharmacogenetics, vol. 14, no. 10, pp. 635–645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. C. S. Song, I. Echchgadda, B.-S. Baek et al., “Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor,” Journal of Biological Chemistry, vol. 276, no. 45, pp. 42549–42556, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Pillot, M. Ouzzine, S. Fournel-Gigleux et al., “Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP-glucuronosyltransferase 2B4,” Journal of Biological Chemistry, vol. 268, no. 34, pp. 25636–25642, 1993. View at Google Scholar · View at Scopus
  32. J. R. M. Plass, O. Mol, J. Heegsma et al., “Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump,” Hepatology, vol. 35, no. 3, pp. 589–596, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ananthanarayanan, N. Balasubramanian, M. Makishima, D. J. Mangelsdorf, and F. J. Suchy, “Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor,” Journal of Biological Chemistry, vol. 276, no. 31, pp. 28857–28865, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Huang, A. Zhao, J.-L. Lew et al., “Farnesoid X receptor activates transcription of the phospholipid pump MDR3,” Journal of Biological Chemistry, vol. 278, no. 51, pp. 51085–51090, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Chen, L. Ma, P. A. Dawson et al., “Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter,” Journal of Biological Chemistry, vol. 278, no. 22, pp. 19909–19916, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Neimark, F. Chen, X. Li, and B. L. Shneider, “Bile acid-induced negative feedback regulation of the human ileal bile acid transporter,” Hepatology, vol. 40, no. 1, pp. 149–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Grobert, I. Zaghini, H. Fujii et al., “Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis- retinoic acid receptor heterodimer,” Journal of Biological Chemistry, vol. 274, no. 42, pp. 29749–29754, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. J.-F. Landrier, J. J. Eloranta, S. R. Vavricka, and G. A. Kullak-Ublick, “The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-α and -β genes,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 290, no. 3, pp. G476–G485, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. L. A. Denson, E. Sturm, W. Echevarria et al., “The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp,” Gastroenterology, vol. 121, no. 1, pp. 140–147, 2001. View at Google Scholar · View at Scopus
  40. D. Jung, B. Hagenbuch, M. Fried, P. J. Meier, and G. A. Kullak-Ublick, “Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 286, no. 5, pp. G752–G761, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Jung and G. A. Kullak-Ublick, “Hepatocyte nuclear factor 1α: a key mediator of the effect of bile acids on gene expression,” Hepatology, vol. 37, no. 3, pp. 622–631, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. E. Andersen, G. Karlaganis, and J. Sjovall, “Altered bile acid profiles in duodenal bile and urine in diabetic subjects,” European Journal of Clinical Investigation, vol. 18, no. 2, pp. 166–172, 1988. View at Google Scholar · View at Scopus
  43. K. Suhre, C. Meisinger, A. Döring et al., “Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting,” PLoS ONE, vol. 5, no. 11, Article ID e13953, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Duran-Sandoval, G. Mautino, G. Martin et al., “Glucose regulates the expression of the farnesoid X receptor in liver,” Diabetes, vol. 53, no. 4, pp. 890–898, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Q. Shih, M. Bussen, E. Sehayek et al., “Hepatocyte nuclear factor-1α is an essential regulator of bile acid and plasma cholesterol metabolism,” Nature Genetics, vol. 27, no. 4, pp. 375–382, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. M. S. Kim, J. Shigenaga, A. Moser, K. Feingold, and C. Grunfeld, “Repression of farnesoid X receptor during the acute phase response,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 8988–8995, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. H. R. Kast, C. M. Nguyen, C. J. Sinal et al., “Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids,” Molecular Endocrinology, vol. 15, no. 10, pp. 1720–1728, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Claudel, Y. Inoue, O. Barbier et al., “Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression,” Gastroenterology, vol. 125, no. 2, pp. 544–555, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. P. A. Mak, H. R. Kast-Woelbern, A. M. Anisfeld, and P. A. Edwards, “Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors,” Journal of Lipid Research, vol. 43, no. 12, pp. 2037–2041, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Sirvent, T. Claudel, G. Martin et al., “The farnesoid X receptor induces very low density lipoprotein receptor gene expression,” FEBS Letters, vol. 566, no. 1–3, pp. 173–177, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Watanabe, S. M. Houten, L. Wang et al., “Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c,” Journal of Clinical Investigation, vol. 113, no. 10, pp. 1408–1418, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. K. E. Matsukuma, M. K. Bennett, J. Huang, L. Wang, G. Gil, and T. F. Osborne, “Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase,” Journal of Lipid Research, vol. 47, no. 12, pp. 2754–2761, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. I. P. Torra, T. Claudel, C. Duval, V. Kosykh, J.-C. Fruchart, and B. Staels, “Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor,” Molecular Endocrinology, vol. 17, no. 2, pp. 259–272, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. R. S. Savkur, K. S. Bramlett, L. F. Michael, and T. P. Burris, “Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor,” Biochemical and Biophysical Research Communications, vol. 329, no. 1, pp. 391–396, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Zhang, L. W. Castellani, C. J. Sinal, F. J. Gonzalez, and P. A. Edwards, “Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR,” Genes and Development, vol. 18, no. 2, pp. 157–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. K. R. Stayrook, K. S. Bramlett, R. S. Savkur et al., “Regulation of carbohydrate metabolism by the farnesoid X receptor,” Endocrinology, vol. 146, no. 3, pp. 984–991, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Duran-Sandoval, B. Cariou, F. Percevault et al., “The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition,” Journal of Biological Chemistry, vol. 280, no. 33, pp. 29971–29979, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Ma, P. K. Saha, L. Chan, and D. D. Moore, “Farnesoid X receptor is essential for normal glucose homeostasis,” Journal of Clinical Investigation, vol. 116, no. 4, pp. 1102–1109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. M. J. Potthoff, J. Boney-Montoya, M. Choi et al., “FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway,” Cell Metabolism, vol. 13, no. 6, pp. 729–738, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Renga, A. Mencarelli, C. D’Amore et al., “Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition,” The FASEB Journal, vol. 26, 7, pp. 3021–3031, 2012. View at Google Scholar
  61. X. Ge, L. Yin, H. Ma, T. Li, J. Y. L. Chiang, and Y. Zhang, “Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis,” Journal of Lipid Research, vol. 52, no. 8, pp. 1561–1568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Caron, C. Huaman Samanez, H. Dehondt et al., “Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes,” Molecular and Cellular Biology, vol. 33, no. 11, pp. 2202–2211, 2013. View at Google Scholar
  63. S. Cipriani, A. Mencarelli, G. Palladino, and S. Fiorucci, “FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats,” Journal of Lipid Research, vol. 51, no. 4, pp. 771–784, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Zhang, F. Y. Lee, G. Barrera et al., “Activation of the nuclear FXR improves hyperglycemia and hyperlipidemia in diabetic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 4, pp. 1006–1011, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Prawitt, M. Abdelkarim, J. H. M. Stroeve et al., “Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity,” Diabetes, vol. 60, no. 7, pp. 1861–1871, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Lee, S. Seok, P. Yu et al., “Genomic analysis of hepatic farnesoid X receptor binding sites reveals altered binding in obesity and direct gene repression by farnesoid X receptor in mice,” Hepatology, vol. 56, no. 1, pp. 108–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. J.-C. Chuang, J.-Y. Cha, J. C. Garmey, R. G. Mirmira, and J. J. Repa, “Nuclear hormone receptor expression in the endocrine pancreas,” Molecular Endocrinology, vol. 22, no. 10, pp. 2353–2363, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. B. Renga, A. Mencarelli, P. Vavassori, V. Brancaleone, and S. Fiorucci, “The bile acid sensor FXR regulates insulin transcription and secretion,” Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1802, no. 3, pp. 363–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. I. R. Popescu, A. Helleboid-Chapman, A. Lucas et al., “The nuclear receptor FXR is expressed in pancreatic β-cells and protects human islets from lipotoxicity,” FEBS Letters, vol. 584, no. 13, pp. 2845–2851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. P. Seyer, D. Vallois, C. Poitry-Yamate et al., “Hepatic glucose sensing is required to preserve β cell glucose competence,” Journal of Clinical Investigation, vol. 123, no. 4, pp. 1662–1676, 2013. View at Google Scholar
  71. M. Dufer, K. Horth, R. Wagner et al., “Bile acids acutely stimulate insulin secretion of mouse -cells via farnesoid X receptor activation and KATP channel inhibition,” Diabetes, vol. 61, no. 6, pp. 1479–1489, 2012. View at Google Scholar
  72. M. Düfer, K. Hörth, P. Krippeit-Drews, and G. Drews, “The significance of the nuclear farnesoid X receptor (FXR) in β cell function,” Islets, vol. 4, no. 5, pp. 333–338, 2012. View at Google Scholar
  73. M. I. Ramirez, D. Karaoglu, D. Haro, C. Barillas, R. Bashirzadeh, and G. Gil, “Cholesterol and bile acids regulate cholesterol 7α-hydroxylase expression at the transcriptional level in culture and in transgenic mice,” Molecular and Cellular Biology, vol. 14, no. 4, pp. 2809–2821, 1994. View at Google Scholar · View at Scopus
  74. J. M. Lehmann, S. A. Kliewer, L. B. Moore et al., “Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway,” Journal of Biological Chemistry, vol. 272, no. 6, pp. 3137–3140, 1997. View at Publisher · View at Google Scholar · View at Scopus
  75. D. J. Peet, S. D. Turley, W. Ma et al., “Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα,” Cell, vol. 93, no. 5, pp. 693–704, 1998. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Rudling, “Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo,” Journal of Lipid Research, vol. 33, no. 4, pp. 493–501, 1992. View at Google Scholar · View at Scopus
  77. L. B. Agellon, V. A. B. Drover, S. K. Cheema, G. Franck Gbaguidi, and A. Walsh, “Dietary cholesterol fails to stimulate the human cholesterol 7α-hydroxylase gene (CYP7A1) in transgenic mice,” Journal of Biological Chemistry, vol. 277, no. 23, pp. 20131–20134, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Goodwin, M. A. Watson, H. Kim, J. Miao, J. K. Kemper, and S. A. Kliewer, “Differential regulation of rat and human CYP7A 1 by the nuclear oxysterol receptor liver X receptor-α,” Molecular Endocrinology, vol. 17, no. 3, pp. 386–394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Verreault, K. Senekeo-Effenberger, J. Trottier et al., “The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice,” Hepatology, vol. 44, no. 2, pp. 368–378, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Uppal, S. P. S. Saini, A. Moschetta et al., “Activation of LXRs prevents bile acid toxicity and cholestasis in female mice,” Hepatology, vol. 45, no. 2, pp. 422–432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Song, R. A. Hiipakka, and S. Liao, “Selective activation of liver X receptor alpha by 6α-hydroxy bile acids and analogs,” Steroids, vol. 65, no. 8, pp. 423–427, 2000. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Venkateswaran, B. A. Laffitte, S. B. Joseph et al., “Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12097–12102, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. J. J. Repa, S. D. Turley, J.-M. A. Lobaccaro et al., “Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers,” Science, vol. 289, no. 5484, pp. 1524–1529, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. N. Wang, D. Lan, W. Chen, F. Matsuura, and A. R. Tall, “ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 26, pp. 9774–9779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. M. A. Kennedy, G. C. Barrera, K. Nakamura et al., “ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation,” Cell Metabolism, vol. 1, no. 2, pp. 121–131, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. P. A. Mak, B. A. Laffitte, C. Desrumaux et al., “Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages: a critical role for nuclear liver X receptors α and β,” Journal of Biological Chemistry, vol. 277, no. 35, pp. 31900–31908, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. B. A. Laffitte, J. J. Repa, S. B. Joseph et al., “LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 2, pp. 507–512, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. B. A. Laffitte, S. B. Joseph, M. Chen et al., “The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions,” Molecular and Cellular Biology, vol. 23, no. 6, pp. 2182–2191, 2003. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Luo and A. R. Tall, “Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element,” Journal of Clinical Investigation, vol. 105, no. 4, pp. 513–520, 2000. View at Google Scholar · View at Scopus
  90. Y. Zhang, J. J. Repa, K. Gauthier, and D. J. Mangelsdorf, “Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ,” Journal of Biological Chemistry, vol. 276, no. 46, pp. 43018–43024, 2001. View at Publisher · View at Google Scholar · View at Scopus
  91. C. Hong, R. Walczak, H. Dhamko et al., “Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target,” Journal of Lipid Research, vol. 52, no. 3, pp. 531–539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. J. N. van der Veen, T. H. van Dijk, C. L. J. Vrins et al., “Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol,” Journal of Biological Chemistry, vol. 284, no. 29, pp. 19211–19219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. J. J. Repa, G. Liang, J. Ou et al., “Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ,” Genes and Development, vol. 14, no. 22, pp. 2819–2830, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. J. R. Schultz, H. Tu, A. Luk et al., “Role of LXRs in control of lipogenesis,” Genes and Development, vol. 14, no. 22, pp. 2831–2838, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Inaba, M. Matsuda, M. Shimamura et al., “Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor,” Journal of Biological Chemistry, vol. 278, no. 24, pp. 21344–21351, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. T. Shimizugawa, M. Ono, M. Shimamura et al., “ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase,” Journal of Biological Chemistry, vol. 277, no. 37, pp. 33742–33748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Shimamura, M. Matsuda, S. Kobayashi et al., “Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes,” Biochemical and Biophysical Research Communications, vol. 301, no. 2, pp. 604–609, 2003. View at Publisher · View at Google Scholar · View at Scopus
  98. J. W. Chisholm, J. Hong, S. A. Mills, and R. M. Lawn, “The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse,” Journal of Lipid Research, vol. 44, no. 11, pp. 2039–2048, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. B. A. Laffitte, L. C. Chao, J. Li et al., “Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5419–5424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. G. Cao, Y. Liang, C. L. Broderick et al., “Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis,” Journal of Biological Chemistry, vol. 278, no. 2, pp. 1131–1136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. T. M. Stulnig, K. R. Steffensen, H. Gao et al., “Novel roles of Liver X receptors exposed by gene expression profiling in liver and adipose tissue,” Molecular Pharmacology, vol. 62, no. 6, pp. 1299–1305, 2002. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Grefhorst, T. H. Van Dijk, A. Hammer et al., “Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice,” American Journal of Physiology-Endocrinology and Metabolism, vol. 289, no. 5, pp. E829–E838, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. S. R. Commerford, L. Vargas, S. E. Dorfman et al., “Dissection of the insulin-sensitizing effect of liver X receptor ligands,” Molecular Endocrinology, vol. 21, no. 12, pp. 3002–3012, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. B. Herzog, M. Hallberg, A. Seth, A. Woods, R. White, and M. G. Parker, “The nuclear receptor cofactor, receptor-interacting protein 140, is required for the regulation of hepatic lipid and glucose metabolism by liver X receptor,” Molecular Endocrinology, vol. 21, no. 11, pp. 2687–2697, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. K. T. Dalen, S. M. Ulven, K. Bamberg, J.-Å. Gustafsson, and H. I. Nebb, “Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor alpha,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 48283–48291, 2003. View at Publisher · View at Google Scholar · View at Scopus
  106. G. U. Schuster, L. Johansson, S. Kietz, T. M. Stulnig, P. Parini, and J.-Å. Gustafsson, “Improved metabolic control by depletion of Liver X Receptors in mice,” Biochemical and Biophysical Research Communications, vol. 348, no. 1, pp. 176–182, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. P. J. Randle, “Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years,” Diabetes and Metabolism Reviews, vol. 14, no. 4, pp. 263–283, 1998. View at Google Scholar
  108. J. L. Collins, “Therapeutic opportunities for liver X receptor modulators,” Current Opinion in Drug Discovery and Development, vol. 7, no. 5, pp. 692–702, 2004. View at Google Scholar · View at Scopus
  109. A. M. L. Pettersson, B. M. Stenson, S. Lorente-Cebrián et al., “LXR is a negative regulator of glucose uptake in human adipocytes,” Diabetologia, vol. 56, pp. 2044–2054, 2013. View at Google Scholar
  110. A. M. Efanov, S. Sewing, K. Bokvist, and J. Gromada, “Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic β-cells,” Diabetes, vol. 53, no. 3, supplement, pp. S75–S78, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Ogihara, J.-C. Chuang, G. L. Vestermark et al., “Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling,” Journal of Biological Chemistry, vol. 285, no. 8, pp. 5392–5404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. H. Zitzer, W. Wente, M. B. Brenner et al., “Sterol regulatory element-binding protein 1 mediates liver X receptor-β-induced increases in insulin secretion and insulin messenger ribonucleic acid levels,” Endocrinology, vol. 147, no. 8, pp. 3898–3905, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Helleboid-Chapman, S. Helleboid, H. Jakel et al., “Glucose regulates LXRα subcellular localization and function in rat pancreatic β-cells,” Cell Research, vol. 16, no. 7, pp. 661–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Amemiya-Kudo, J. Oka, T. Ide et al., “Sterol regulatory element-binding proteins activate insulin gene promoter directly and indirectly through synergy with BETA2/E47,” Journal of Biological Chemistry, vol. 280, no. 41, pp. 34577–34589, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. I. Gerin, V. W. Dolinsky, J. G. Shackman et al., “LXRβ is required for adipocyte growth, glucose homeostasis, and β cell function,” Journal of Biological Chemistry, vol. 280, no. 24, pp. 23024–23031, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. W. Wente, M. B. Brenner, H. Zitzer, J. Gromada, and A. M. Efanov, “Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells,” Endocrinology, vol. 148, no. 4, pp. 1843–1849, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. Z. X. Meng, J. Nie, J. J. Ling et al., “Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest,” Diabetologia, vol. 52, no. 1, pp. 125–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. H. Liang, Y. Zhong, S. Zhou, and Q. Q. Li, “Palmitic acid-induced apoptosis in pancreatic β-cells is increased by liver X receptor agonist and attenuated by eicosapentaenoate,” In Vivo, vol. 25, no. 5, pp. 711–718, 2011. View at Google Scholar · View at Scopus
  119. S. S. Choe, A. H. Choi, J.-W. Lee et al., “Chronic activation of liver X receptor induces β-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic β-cells,” Diabetes, vol. 56, no. 6, pp. 1534–1543, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. I. Matsuura, N. G. Denissova, G. Wang, D. He, J. Long, and F. Liu, “Cyclin-dependent kinases regulate the antiproliferative function of Smads,” Nature, vol. 430, no. 6996, pp. 226–231, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. G. M. Wildey, S. Patil, and P. H. Howe, “Smad3 potentiates transforming growth factor β (TGFβ)-induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes,” Journal of Biological Chemistry, vol. 278, no. 20, pp. 18069–18077, 2003. View at Publisher · View at Google Scholar · View at Scopus
  122. C. D. Green, D. B. Jump, and L. K. Olson, “Elevated insulin secretion from liver X receptor-activated pancreatic β-cells involves increased de novo lipid synthesis and triacylglyceride turnover,” Endocrinology, vol. 150, no. 6, pp. 2637–2645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  123. D. L. Eizirik, D. G. Pipeleers, Z. Ling, N. Welsh, C. Hellerström, and A. Andersson, “Major species differences between humans and rodents in the susceptibility to pancreatic β-cell injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 20, pp. 9253–9256, 1994. View at Google Scholar · View at Scopus
  124. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, “β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes,” Diabetes, vol. 52, no. 1, pp. 102–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  125. S. Costes, R. Langen, T. Gurlo, A. V. Matveyenko, and P. C. Butler, “β-Cell failure in type 2 diabetes: a case of asking too much of too few?” Diabetes, vol. 62, no. 2, pp. 327–335, 2013. View at Google Scholar
  126. E. J. P. De Koning, N. L. Bodkin, B. C. Hansen, and A. Clark, “Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population,” Diabetologia, vol. 36, no. 5, pp. 378–384, 1993. View at Google Scholar · View at Scopus
  127. T. Tomita, “Islet amyloid polypeptide in pancreatic islets from type 2 diabetic subjects,” Islets, vol. 4, no. 3, pp. 223–332, 2012. View at Google Scholar
  128. T. Kakuma, Y. Lee, M. Higa et al., “Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 15, pp. 8536–8541, 2000. View at Publisher · View at Google Scholar · View at Scopus
  129. H. Murakami, N. Tamasawa, J. Matsui, M. Yasujima, and T. Suda, “Plasma oxysterols and tocopherol in patients with diabetes mellitus and hyperlipidemia,” Lipids, vol. 35, no. 3, pp. 333–338, 2000. View at Google Scholar · View at Scopus
  130. A. Garg and S. M. Grundy, “Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial,” Annals of Internal Medicine, vol. 121, no. 6, pp. 416–422, 1994. View at Google Scholar · View at Scopus
  131. V. A. Fonseca, J. Rosenstock, A. C. Wang, K. E. Truitt, and M. R. Jones, “Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy,” Diabetes Care, vol. 31, no. 8, pp. 1479–1484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. R. B. Goldberg, V. A. Fonseca, K. E. Truitt, and M. R. Jones, “Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy,” Archives of Internal Medicine, vol. 168, no. 14, pp. 1531–1540, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. M. J. Potthoff, A. Potts, T. He et al., “Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 304, no. 4, pp. G371–G380, 2013. View at Google Scholar
  134. L. Chen, X. Yao, A. Young et al., “Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes,” American Journal of Physiology-Endocrinology and Metabolism, vol. 302, no. 1, pp. E68–E76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  135. Y. Wu, C. J. Aquino, D. J. Cowan et al., “Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes,” Journal of Medicinal Chemistry, vol. 56, no. 12, pp. 5094–5114, 2013. View at Google Scholar
  136. S. Mudaliar, R. R. Henry, A. J. Sanyal et al., “Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease,” Gastroenterology, vol. 145, pp. 574–582, 2013. View at Google Scholar
  137. Y. T. Ghebremariam, K. Yamada, J. C. Lee et al., “FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats,” PLoS ONE, vol. 8, no. 4, Article ID e60653, 2013. View at Google Scholar
  138. L. Jin, X. Feng, H. Rong et al., “The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism,” Nature Communications, vol. 4, p. 1937, 2013. View at Google Scholar
  139. Y. Jia, M. H. Hoang, H.-J. Jun, J. H. Lee, and S.-J. Lee, “Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 14, pp. 4185–4190, 2013. View at Google Scholar
  140. Y. Avior, D. Bomze, O. Ramon, and Y. Nahmias, “Flavonoids as dietary regulators of nuclear receptor activity,” Food and Function, vol. 4, no. 6, p. 831, 2013. View at Google Scholar
  141. I. Dahlman, M. Nilsson, H. F. Gu et al., “Functional and genetic analysis in type 2 diabetes of Liver X receptor alleles—a cohort study,” BMC Medical Genetics, vol. 10, article 27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. K. Solaas, V. Legry, K. Retterstol et al., “Suggestive evidence of associations between liver X receptor β polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe),” BMC Medical Genetics, vol. 11, no. 1, article 144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Katz, C. Udata, E. Ott et al., “Safety, pharmacokinetics, and pharmacodynamics of single doses of lxr-623, a novel liver X-receptor agonist, in healthy participants,” Journal of Clinical Pharmacology, vol. 49, no. 6, pp. 643–649, 2009. View at Publisher · View at Google Scholar · View at Scopus
  144. D. H. Volle, K. Mouzat, R. Duggavathi et al., “Multiple roles of the nuclear receptors for oxysterols liver X receptor to maintain male fertility,” Molecular Endocrinology, vol. 21, no. 5, pp. 1014–1027, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. S. M. Houten, D. H. Volle, C. L. Cummins, D. J. Mangelsdorf, and J. Auwerx, “In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue,” Molecular Endocrinology, vol. 21, no. 6, pp. 1312–1323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  146. F.-Z. El-Hajjaji, A. Oumeddour, A. J. C. Pommier et al., “Liver X receptors, lipids and their reproductive secrets in the male,” Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1812, no. 8, pp. 974–981, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. K. Mouzat, F. Volat, S. Baron et al., “Absence of nuclear receptors for oxysterols liver X receptor induces ovarian hyperstimulation syndrome in mice,” Endocrinology, vol. 150, no. 7, pp. 3369–3375, 2009. View at Publisher · View at Google Scholar · View at Scopus